Kontafarma China Holdings Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Chaowen Jiang
Chief executive officer
HK$2.8m
Total compensation
| CEO salary percentage | 60.9% |
| CEO tenure | 6.3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.6yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?
Dec 28
Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Sep 01Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Dec 29Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?
Sep 15Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?
Apr 20Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?
Nov 04Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares
Feb 18These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -HK$29m |
| Sep 30 2023 | n/a | n/a | -HK$12m |
| Jun 30 2023 | n/a | n/a | HK$5m |
| Mar 31 2023 | n/a | n/a | -HK$40m |
| Dec 31 2022 | HK$3m | HK$2m | -HK$85m |
| Sep 30 2022 | n/a | n/a | -HK$24m |
| Jun 30 2022 | n/a | n/a | -HK$10m |
| Mar 31 2022 | n/a | n/a | -HK$29m |
| Dec 31 2021 | HK$3m | HK$1m | -HK$48m |
| Jun 30 2021 | n/a | n/a | -HK$119m |
| Mar 31 2021 | n/a | n/a | -HK$81m |
| Dec 31 2020 | HK$2m | HK$2m | -HK$42m |
| Jun 30 2020 | n/a | n/a | HK$66m |
| Mar 31 2020 | n/a | n/a | HK$60m |
| Dec 31 2019 | HK$2m | HK$2m | HK$54m |
| Sep 30 2019 | n/a | n/a | HK$29m |
| Jun 30 2019 | n/a | n/a | HK$22m |
| Mar 31 2019 | n/a | n/a | HK$27m |
| Dec 31 2018 | HK$2m | HK$2m | HK$32m |
| Sep 30 2018 | n/a | n/a | HK$12m |
| Jun 30 2018 | n/a | n/a | -HK$8m |
| Mar 31 2018 | n/a | n/a | -HK$5m |
| Dec 31 2017 | HK$1m | HK$57k | -HK$2m |
Compensation vs Market: Chaowen's total compensation ($USD356.48K) is above average for companies of similar size in the Hong Kong market ($USD234.20K).
Compensation vs Earnings: Chaowen's compensation has increased whilst the company is unprofitable.
CEO
Chaowen Jiang (58 yo)
6.3yrs
Tenure
HK$2,788,000
Compensation
Mr. Chaowen Jiang is Chief Executive Officer of Tongfang Kontafarma Holdings Ltd since December 11, 2017 and its Executive Director since January 23, 2018. He has been Vice President at Kontafarma China Ho...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 2.6yrs | no data | no data | |
| VP, CEO & Executive Director | 6.3yrs | HK$2.79m | no data | |
| Executive Director | 2yrs | no data | no data | |
| VP, CFO & Company Secretary | 9.4yrs | no data | no data | |
| VP & COO | 3.6yrs | no data | no data |
3.6yrs
Average Tenure
51yo
Average Age
Experienced Management: 1312's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 2.6yrs | no data | no data | |
| VP, CEO & Executive Director | 6.3yrs | HK$2.79m | no data | |
| Executive Director | 3.6yrs | no data | no data | |
| Independent Non-Executive Director | 12.3yrs | HK$118.00k | no data | |
| Independent Non-Executive Director | 9.8yrs | HK$118.00k | no data | |
| Non-Executive Director | 10.1yrs | HK$2.01m | no data | |
| Independent Non-Executive Director | 8.7yrs | HK$118.00k | no data |
8.7yrs
Average Tenure
53yo
Average Age
Experienced Board: 1312's board of directors are considered experienced (8.7 years average tenure).